Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

The Effect of n-3 Fatty Acid Supplementation on Serum Levels, and Gene Expression of type2 Diabetes Patient

17. november 2015 opdateret af: Tehran University of Medical Sciences

The Effect of n-3 Fatty Acid Supplementation on the Expression of Sirt-1, Adiponectin Receptor 1 (AdipoR1) & Adiponectin Receptor 2 (AdipoR2) Genes of PBMC and Circulatory Levels of Resistin,Monocyte Chemotactic Protein (MCP-1) and Adiponectin of type2 Diabetes Patient

The aim of this study is to determine the effects of supplementation with n-3 fatty acid or placebo for 10 weeks on the expression of Sirt-1, AdipoR1 & AdipoR2 genes in the peripheral blood mononuclear cell (PBMC) and circulatory levels of Resistin, MCP-1 and Adiponectin of type2 diabetes patient

Studieoversigt

Status

Ukendt

Detaljeret beskrivelse

The aim of this study is to determine of the effects of supplementation with n-3 fatty acid or placebo for 10 weeks on the expression of Sirt-1, AdipoR1(adiponectin receptor 1) & AdipoR2 (adiponectin receptor 2) genes in the peripheral blood mononuclear cell (PBMC) and circulatory levels of Resistin, MCP-1 (Monocyte Chemoattractant Protein-1) and Adiponectin of type2 diabetes patient. In this randomized, double-blind clinical trial, placebo-controlled, 88 men and women with type 2 diabetes are enrolled in the study from the Iranian Diabetes Association. After signing informed consent all individuals complete a general information form , 24-hour food recall for 3 days and beck depression questionnaire will be taken from the participants at the beginning and the end of the study. Selected samples are randomly classified into 2 blocks of groups receiving supplement and placebo. The supplement group, will receive mg 1800mg EPA(Eicosapentaenoic acid ) & 900mg DHA( docosahexaenoic acid) (total=2700mg) for 10 weeks and the placebo group will also receive placebo (containing 2700 mg of edible paraffin) (similar in terms of color, shape and size). Patients are recommended to sustain their diets and medication dose (s) during the study and also advised to maintain a constant level of physical activity. Blood samples will be collected after 12 hours fasting and anthropometric variables, biochemical parameters, target gene expression and physical activity before and after the trial will be measured

Undersøgelsestype

Interventionel

Tilmelding (Forventet)

88

Fase

  • Fase 4

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

30 år til 65 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • willingness to participation,
  • diabetic patients 30- 60 years old,
  • body mass index in the range 25-40,
  • avoidance of dietary supplements,
  • vitamins and herbal products at least 3 months before and throughout the intervention

Exclusion Criteria:

  • people who have used n-3 Fatty Acid Supplementation in last 3 months,
  • having chronic renal disease ,
  • GI disease,
  • Hepatobiliary diseases,
  • hematological disorders,
  • hypo- or hyperthyroidism,
  • type 1 diabetes,
  • treatment with orlistat or sibutramine for weight loss,
  • pregnancy and lactation,
  • treatment with insulin or Thiazolidinediones.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Støttende pleje
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: n-3 Fatty Acid Supplemetation
patients with Type II Diabetes who receive 3 cap omega3, 3 times a day, for 10 weeks.
n-3 Fatty Acid supplement, 3 × 1000 mg softgel daily (2700 mg EPA+DHA per day), 3 times a day, for 10 weeks.
Andre navne:
  • n-3 PUFA
  • Omega 3
Placebo komparator: Placebo
patients with Type II Diabetes who receive 3 cap of placebo/ for 10 weeks.
3 cap 1 g Placebo(paraffin) per day for 10 weeks. Control Group: n-3 Fatty Acid placebo softgel (Containing 3 g edible paraffin oil), 3 × 1000 mg softgel daily (3 g per day), 3 times a day, for 10 weeks.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Serum Fasting Blood Sugar(FBS)
Tidsramme: Change from baseline at 10 weeks
Change from baseline at 10 weeks

Sekundære resultatmål

Resultatmål
Tidsramme
Serum Insulin
Tidsramme: Change from baseline at 10 weeks
Change from baseline at 10 weeks
Serum HbA1C
Tidsramme: Change from baseline at 10 weeks
Change from baseline at 10 weeks
Serum Resistin
Tidsramme: Change from baseline at 10 weeks
Change from baseline at 10 weeks
Serum adiponectin
Tidsramme: Change from baseline at 10 weeks
Change from baseline at 10 weeks
Serum mcp-1
Tidsramme: Change from baseline at 10 weeks
Change from baseline at 10 weeks
Gene Expression of AdipoR1
Tidsramme: Change from baseline at 10 weeks
Change from baseline at 10 weeks
Gene Expression of AdipoR2
Tidsramme: Change from baseline at 10 weeks
Change from baseline at 10 weeks
Gene Expression of Sirt-1
Tidsramme: Change from baseline at 10 weeks
Change from baseline at 10 weeks
Beck depression score
Tidsramme: Change from baseline at 10 weeks
Change from baseline at 10 weeks
Serum cholesterol
Tidsramme: Change from baseline at 10 weeks
Change from baseline at 10 weeks
Serum LDL cholesterol
Tidsramme: Change from baseline at 10 weeks
Change from baseline at 10 weeks
Serum TG
Tidsramme: Change from baseline at 10 weeks
Change from baseline at 10 weeks
Serum HDL cholesterol
Tidsramme: Change from baseline at 10 weeks
Change from baseline at 10 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. september 2014

Primær færdiggørelse (Forventet)

1. januar 2016

Studieafslutning (Forventet)

1. februar 2016

Datoer for studieregistrering

Først indsendt

7. oktober 2014

Først indsendt, der opfyldte QC-kriterier

9. oktober 2014

Først opslået (Skøn)

10. oktober 2014

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

18. november 2015

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

17. november 2015

Sidst verificeret

1. november 2015

Mere information

Begreber relateret til denne undersøgelse

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner